ClinicalTrials.gg
CompletedNCT00413413Updated Apr 28, 2011Results posted

Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension

A Phase 3 interventional study of Valsartan/amlodipine 80/5 mg and Valsartan 80 mg in Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 19 sites in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-04-28.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,134
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
15th of 139
1,134 · median 198
Started
2007
with 11 others
Phase 3
53 of 140
none open now
Registered
67th of 140
by date
Lead sponsor
19 of 140
Novartis Pharmaceuticals

Among the 140 studies testing valsartan in Hypertension, this one is the 15th largest by enrollment of the 139 interventional ones that give a count, is one of 12 that started in 2007, is one of 53 in phase 3, and was the 67th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

This study evaluated the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Hypertension, valsartan, amlodipine, high blood pressure
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female outpatients >= 18 years and \< 86 years
  • Patients with essential diastolic hypertension
  • At visit 1, the patient must have mean sitting diastolic blood pressure >= 95 mmHg and \< 10 mmHg; patients treated with antihypertensive medication must have a mean sitting diastolic blood pressure \< 100 mmHg
  • At visit 2, patients must have a mean sitting diastolic blood pressure of >= 95 mmHg and \< 100 mmHg
  • At visit 3, patients must have a mean sitting diastolic blood pressure of >= 90 mmHg and \< 110 mmHg

Exclusion criteria

Exclusion Criteria:

  • Severe hypertension >= 180/110 mmHg
  • Known or suspected , including a history of allergy or to valsartan or amlodipine or to other drugs with similar chemical structures
  • Inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to Visit 2
  • History of hypertensive encephalopathy, cerebrovascular accident or , myocardial infarction or other types of revascularization
  • Malignant hypertension
  • All patients with Type I diabetes and those patients with Type 2 diabetes who are not well controlled based on the investigator's clinical judgment
  • Pregnant or nursing women
  • History of heart failure
  • Angina pectoris
  • Second or third degree heart block
  • Life threatening or symptomatic arrhythmias
  • valvular heart disease
  • Evidence of a secondary form of hypertension
  • Known or moderate malignant retinopathy
  • Evidence of hepatic disease
  • Evidence of renal impairment

Other protocol-defined exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,134 participants (actual)

Study arms

  • Experimental
    Valsartan/amlodipine 80/5 mg

    Drug: Valsartan/amlodipine 80/5 mg

  • Active comparator
    Valsartan 80 mg

    Drug: Valsartan 80 mg

  • Active comparator
    Valsartan 160 mg

    Drug: Valsartan 160 mg

Interventions

  • DrugValsartan/amlodipine 80/5 mg

    1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily

  • DrugValsartanStudies of ValsartanValsartan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily

  • DrugValsartanStudies of ValsartanValsartan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)

    Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

    Time frame: Baseline to end of study (Week 8)

Secondary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)

    Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

    Time frame: Baseline to end of study (Week 8)

  2. Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8)

    A diastolic blood pressure response was defined as a msDBP \< 90 mmHg or a ≥ 10 mmHg decrease compared to baseline at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

    Time frame: Baseline to end of study (Week 8)

  3. Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8)

    Diastolic blood pressure control was defined as a msDBP \< 90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

    Time frame: End of study (Week 8)

  4. Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)

    Overall blood pressure control rate was defined as a msSBP/msDBP \< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

    Time frame: End of study (Week 8)

07

Results

Posted Sep 14, 2009

Participant flow

A total of 1134 patients were enrolled into the single-blind period of the study, and 216 (19%) were discontinued. In total, 918 patients were randomized to the three treatment groups.

Single-Blind
Participant flow — Single-Blind
MilestoneValsartan/Amlodipine 80/5 mgValsartan 80 mgValsartan 160 mg
Started011340
Completed09180
Not completed02160
Withdrew: Adverse event090
Withdrew: Lack of efficacy050
Withdrew: Subject no longer requires study drug01510
Withdrew: Protocol violation0160
Withdrew: Withdrawal by subject0270
Withdrew: Lost to follow-up080
Double-Blind
Participant flow — Double-Blind
MilestoneValsartan/Amlodipine 80/5 mgValsartan 80 mgValsartan 160 mg
Started308307303
Completed293293285
Not completed151418
Withdrew: Adverse event605
Withdrew: Unsatisfactory therapeutic effect121
Withdrew: Protocol deviation121
Withdrew: Subject withdrew consent469
Withdrew: Lost to follow-up342

Outcome measures

PrimaryChange in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)

Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mmHg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
mmHgValsartan/Amlodipine 80/5 mgValsartan 80 mgValsartan 160 mg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)-10.8 ± 0.42-6.3 ± 0.42-7.2 ± 0.42
SecondaryChange in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)

Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mmHg
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
mmHgValsartan/Amlodipine 80/5 mgValsartan 80 mgValsartan 160 mg
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)-12.5 ± 0.61-6.0 ± 0.62-7.7 ± 0.62
SecondaryPercentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8)

A diastolic blood pressure response was defined as a msDBP \< 90 mmHg or a ≥ 10 mmHg decrease compared to baseline at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8)
Percentage of patientsValsartan/Amlodipine 80/5 mgValsartan 80 mgValsartan 160 mg
Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8)77.957.866.6
SecondaryPercentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8)

Diastolic blood pressure control was defined as a msDBP \< 90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

Time frame:
End of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8)
Percentage of patientsValsartan/Amlodipine 80/5 mgValsartan 80 mgValsartan 160 mg
Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8)74.453.664.2
SecondaryPercentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)

Overall blood pressure control rate was defined as a msSBP/msDBP \< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.

Time frame:
End of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)
Percentage of patientsValsartan/Amlodipine 80/5 mgValsartan 80 mgValsartan 160 mg
Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)70.544.158.6

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan/Amlodipine 80/5 mg—4/308 (1.3%)0/308 (0%)
Valsartan 80 mg—0/307 (0%)0/307 (0%)
Valsartan 160 mg—4/303 (1.3%)0/303 (0%)
Most frequent serious events
Most frequent serious events
EventValsartan/Amlodipine 80/5 mgValsartan 80 mgValsartan 160 mg
Cerebral infarctionNervous system disorders0/3080/3073/303
LeukopeniaBlood and lymphatic system disorders0/3080/3071/303
Retinal haemorrhageEye disorders1/3080/3070/303
Abdominal injuryInjury, poisoning and procedural complications1/3080/3070/303
Liver function test abnormalInvestigations1/3080/3070/303
Transient ischaemic attackNervous system disorders1/3080/3070/303

Baseline characteristics

Age Continuous
Age Continuous(years)Valsartan/Amlodipine 80/5 mgValsartan 80 mgValsartan 160 mgTotal
Mean51.6 ± 10.851.7 ± 8.951.2 ± 9.651.5 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan/Amlodipine 80/5 mgValsartan 80 mgValsartan 160 mgTotal
Female127115104346
Male181191198570
08

Study locations

19 sites
  • Beijing ChaoYang Hospital, Affiliate of Capital University of Medical Sciences
    Beijing, 100020, China
  • Beijing General Hospital of Beijing Military Region
    Beijing, 100700, China
  • Beijing Hospital
    Beijing, 100730, China
  • The First People's Hospital of Hangzhou
    Hangzhou, 310006, China
  • The Second Affiliated Hospital of Medical College of Zhejiang University
    Hangzhou, 310006, China
  • The First Affiliated Hospital of Medical College of Zhejiang University
    Hangzhou, 310007, China
  • Southeast University Affiliated Zhong Da Hospital
    Nanjing, 210009, China
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, 210029, China
  • Second Military Medical University Affiliated Changzheng Hospital
    Shanghai, 200003, China
  • Department of cardiology, Ruijin hospital;
    Shanghai, 200025, China
  • Department of cardiology, Ruijin hospital
    Shanghai, 200025, China
  • Fudan University affiliated zhongshan hospital
    Shanghai, 200032, China
  • Second Military Medical University Affiliated Changhai Hospital
    Shanghai, 200433, China
  • The First Affiliated Hospital of China Medical University
    Shenyang, 110001, China
  • The people's Hospital of Liaoning Province
    Shenyang, 110016, China
  • Second Hospital of Hebei University of Medical Sciences
    Shijiazhuang, 050050, China
  • The People's Hospital of Hebei Provincial
    Shijiazhuang, 050051, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, 215004, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, 215006, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2009, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2006
First posted
Dec 19, 2006
Start
Jan 2007
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Results first posted
Sep 14, 2009
Last update
Apr 28, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00413413
First posted
Dec 19, 2006
Start date
Jan 2007
Primary completion
Nov 2007
Completion
Nov 2007
Results posted
Sep 14, 2009
Last update
Apr 28, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valsartan

Start the discussion